Prostate Cancer UK
13
3
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
15.4%
2 terminated/withdrawn out of 13 trials
66.7%
-19.8% vs industry average
15%
2 trials in Phase 3/4
75%
3 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Role: collaborator
The PROSECCA Study, Answering New Questions in Prostate Cancer
Role: collaborator
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
Role: collaborator
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
Role: collaborator
Combination Study of AZD5069 and Enzalutamide.
Role: collaborator
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
Role: collaborator
Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
Role: collaborator
PROSAIC-DS Study (PROState AI in Cancer - Decision Support)
Role: collaborator
Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer
Role: collaborator
Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer
Role: collaborator
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
Role: collaborator
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
Role: collaborator
A Couple Support Intervention for Prostate Cancer
Role: collaborator
All 13 trials loaded